Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349622 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial Ceftriaxone in Subjects With ALS
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 513
- Enrollment target
NCT00349622: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00349622 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 513 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349622, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 513 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).
Interventions
- OTHER placebo
- DRUG ceftriaxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2006-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349622
The ClinicalTrials.gov registry entry for NCT00349622 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 513 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00349622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00349622 about?
NCT00349622 is a clinical study titled "Clinical Trial Ceftriaxone in Subjects With ALS". The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).
What is the current status of trial NCT00349622?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 513 participants. The study started on 2006-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00349622?
The interventions under investigation include: placebo (OTHER), ceftriaxone (DRUG).
Who is sponsoring clinical trial NCT00349622?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.